Protara Therapeutics, Inc.
TARA
$3.97
$0.030.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.51% | 21.93% | 23.73% | 21.34% | 36.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.62% | 38.98% | 33.31% | 19.71% | 55.58% |
| Operating Income | -40.62% | -38.98% | -33.31% | -19.71% | -55.58% |
| Income Before Tax | -44.84% | -49.25% | -35.54% | -18.17% | -57.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.84% | -49.25% | -35.54% | -18.17% | -57.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.84% | -49.25% | -35.54% | -18.17% | -57.26% |
| EBIT | -40.62% | -38.98% | -33.31% | -19.71% | -55.58% |
| EBITDA | -41.02% | -39.16% | -33.42% | -19.81% | -55.87% |
| EPS Basic | -0.37% | -5.57% | 22.19% | 37.58% | 21.00% |
| Normalized Basic EPS | -0.36% | -5.63% | 22.19% | 37.58% | 21.00% |
| EPS Diluted | -0.37% | -5.57% | 22.19% | 37.58% | 21.00% |
| Normalized Diluted EPS | -0.36% | -5.63% | 22.19% | 37.58% | 21.00% |
| Average Basic Shares Outstanding | 44.32% | 41.35% | 74.18% | 89.31% | 99.08% |
| Average Diluted Shares Outstanding | 44.32% | 41.35% | 74.18% | 89.31% | 99.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |